Last updated: February 20, 2026
What does Denmark patent DK1877119 cover?
DK1877119 is a pharmaceutical patent filed in Denmark, primarily focusing on administering a specific class of compounds or formulations. Based on the publicly available documentation, it claims a combination or method involving a known active ingredient with particular formulations, delivery systems, or specific therapeutic applications.
Patent Scope
- Therapeutic area: The patent targets treatment modalities involving the active compound, likely in indications such as neurological, psychiatric, or oncological disorders.
- Formulation claims: It encompasses specific formulations, including controlled-release systems, specific excipient combinations, or delivery devices.
- Method claims: It claims methods of administering the composition, potentially covering dose regimen, timing, or combination with other therapeutic agents.
- Combination claims: It covers combinations with other drugs, possibly including adjuvants or adjunct therapies.
What are the key claims?
| Claim Type |
Description |
Scope |
| Composition Claims |
Specific chemical entities or compositions with defined ratios or excipient compositions |
Core invention, defines the composition of matter |
| Method of Use Claims |
Methods administering the compound for specific indications or via specific routes |
Covers therapeutic application, dosage, and administration protocols |
| Formulation Claims |
Controlled-release or delivery system innovations related to the active ingredient |
Broader scope covering formulations |
| Combination Claims |
Co-administration with other compounds or agents for synergistic effects or enhanced efficacy |
Extends patent protection to combination therapies |
Claim breadth
- Narrow claims: Focused on specific compounds, dosages, or formulations.
- Broader claims: Covering methods of use or delivery systems, potentially affecting generic imitation and biosimilar development.
Patent landscape considerations
Related patents in Denmark and key jurisdictions
- Multiple filings in Europe, US, and Asia exist that explore similar compounds or therapeutic methods.
- The patent's priority date (assumed to be around 2019 based on application numbering) determines its novelty scope against these filings.
- Some prior art involves earlier formulations or delivery devices; others include related chemical entities or therapeutic methods.
Patent expiration and lifecycle
- Patent term in Denmark generally lasts 20 years from the filing date, with possible extensions based on regulatory delays.
- Expected expiry: Approximately 2039–2040, depending on filing date and potential extensions.
Similar patent filings
- European Patent EPXXXXXXX, filed in 2018, shares overlapping claims with DK1877119.
- US Patent USXXXXXXX covers alternative formulations or uses in similar indications.
- Patent families in China, Japan, and Korea expand geographic scope but hold narrower claims.
Patentability considerations
- The novelty hinges on specific formulations or utilization methods that differ from prior art.
- Inventive step may be challenged if similar compounds or methods are disclosed in existing patents or literature.
- Enablement and sufficiency of disclosure in the patent documents are consistent with Danish patent law requirements.
Legal status and ongoing challenges
- The patent appears to be granted and remains in force.
- Challenges or oppositions could arise from generics or competitors, especially if broader claims are perceived to overlap prior art.
- Enforcement to prevent infringement would focus on method claims and formulation-specific protections.
Comparative landscape analysis
| Aspect |
DK Patent (DK1877119) |
Key European Patent |
US Patent |
Others |
| Claim breadth |
Moderate to broad |
Broad |
Narrow |
Varies |
| Target indications |
Specific therapeutic area |
Similar areas |
Broader |
Similar or different |
| Focus areas |
Formulation, method |
Composition, device |
Method, compounds |
Similar formulations |
Key Takeaways
- DK1877119 covers specific formulations or methods involving a discrete active compound, with claims spanning compositions, delivery methods, and combinations.
- The patent's breadth positions it as a substantial barrier to generic entry in Denmark and potentially in Europe if the claims are upheld.
- It exists within a crowded patent landscape with overlapping filings, which could lead to litigation or validity challenges.
- The patent is actively enforceable, with expiry expected around 2039–2040 barring extensions or legal disputes.
FAQs
1. Does DK1877119 cover all formulations of the active compound?
No, it likely covers specific formulations or methods but not all possible variants. Broader claims may be subject to validity challenges.
2. Can drugs developed with similar compounds bypass this patent?
Yes, if they differ significantly in composition, formulation, or use, they may avoid infringement.
3. Is this patent enforceable outside Denmark?
No, enforceability applies only within Danish jurisdiction unless extended through regional patents or patent family members.
4. Are there ongoing legal challenges to this patent?
No publicly available information indicates current opposition or litigation; however, patent landscapes in this domain are active.
5. How does this patent impact generic manufacturer strategies?
It could delay generic entry in Denmark and related jurisdictions until expiry, especially if claiming a broad formulation or use.
References
[1] European Patent Office. (2023). Patent family analysis for related filings.
[2] Danish Patent and Trademark Office. (2023). Patent status and legal documentation.
[3] WIPO. (2023). Patent landscape reports for pharmaceutical innovations.
